MASTERMIND - Understanding Individual Variation in Treatment Response in Type 2 Diabetes (Mastermind)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01847144 |
Recruitment Status :
Completed
First Posted : May 6, 2013
Last Update Posted : June 21, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Response to treatment in Type 2 Diabetes is highly variable; the same medicine may have little effect in one person but a large effect in another. Understanding mechanisms of altered response to treatment could aid treatment selection and assist the design of new medications with lower nonresponse rates.
This study will examine the physiological mechanisms and potential clinical/biomarker predictors of altered response to sulphonylurea and DPPIV inhibitor glucose lowering medication and answer fundamental methodological questions for the future study of variation in treatment response in Type 2 Diabetes. Participants will withdraw sulphonylurea therapy for up to 2 weeks with assessment of baseline characteristics and glycaemic response. Participants will then enter an optional extension where they receive sulphonylurea or DPPIV inhibitor therapy in crossover fashion.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Type 2 Diabetes | Drug: Gliclazide 80mg OD Drug: Sitagliptin 100mg OD | Phase 4 |
Participants will withdraw sulphonylurea therapy for up to 2 weeks (part 1) followed by an optional cross-over extension (part 2)where they are randomized to 4 weeks of treatment with Gliclazide (DPP-IV thera) or Sitagliptin (sulphonylurea), followed by 4 weeks of the second treatment with a 2 week wash-out period in between.
Part 1 will allow assessment of response rates to long standing sulphonylurea treatment in clinical practice and potential predictors of this, as well as whether a very brief period (1 week) of treatment withdrawal is a valid assessment of an individual's response to therapy. Part 2 will allow comparison of the approach in part one with response to the same treatment in a trial setting and will allow assessment on whether response is consistent across therapies with different mechanisms of action.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 143 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Basic Science |
Official Title: | MASTERMIND - Understanding Individual Variation in Treatment Response in Type 2 |
Study Start Date : | April 2013 |
Actual Primary Completion Date : | February 2015 |
Actual Study Completion Date : | February 2015 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Gliclazide - Sitagliptin
Gliclazide 80mg OD and Sitagliptin 100mg OD
|
Drug: Gliclazide 80mg OD
Gliclazide 80mg OD (DPP-IV inhibitor) - for 4 weeks duration followed by a 2 week wash-out period.
Other Name: DPP-IV inhibitor |
Active Comparator: Sitagliptin - Gliclazide
Gliclazide 80mg OD and Sitagliptin 100mg OD
|
Drug: Sitagliptin 100mg OD
Sitagliptin 100mg OD (sulphonylurea)- for 4 weeks duration followed by a 2 week wash-out period.
Other Name: sulphonylurea OD |
- Change in fasting glucose [ Time Frame: 4 weeks post treatment change ]Change in fasting glucose from 0 to 4 weeks post treatment change.
- Additional changes in biochemical results [ Time Frame: 4 weeks ]Secondary outcome measures will include change in glycosylated albumin, HbA1c, home glucose day profile and mixed meal area under the curve glucose

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 19 Years to 79 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age >18 and <80
- Clinical diagnosis of Type 2 Diabetes
- Currently treated with sulphonylurea tablets
- No change in diabetes treatment (new treatments or dose change) within last 3 months
- Last HbA1c (taken within last 12 months) of ≥42 mmol/mol and ≤75 mmol/mol (6-9%)
- Able and willing to monitor home blood glucose
- Able and willing to give informed consent
Exclusion Criteria:
- Current treatment includes: insulin, GLP-1 agonists, DPP-IV inhibitors, glinides
- Renal impairment (eGFR <30 ml/min/1.73m2)
- Active infection (any infection requiring antibiotics at present)
- Recent (within 3 months) surgery or planned surgery
- Cardiovascular disease (angina, myocardial infarction, stroke, transient ischemic episode) occurring within the previous 3 months
- Previous history of pancreatitis
- Pregnant, breastfeeding or planning a pregnancy over the study period
- Unable/unwilling to monitor home blood glucose

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01847144
United Kingdom | |
NIHR Exeter Clinical Research Facility, Royal Devon & Exeter NHS Foundation Trust | |
Exeter, Devon, United Kingdom, EX2 5DW |
Principal Investigator: | Andrew T Hattersley, FRCP, DM, BM | University of Exeter |
Responsible Party: | Royal Devon and Exeter NHS Foundation Trust |
ClinicalTrials.gov Identifier: | NCT01847144 |
Other Study ID Numbers: |
CRF111 MR/K005707/1 ( Other Grant/Funding Number: MRC grant reference ) |
First Posted: | May 6, 2013 Key Record Dates |
Last Update Posted: | June 21, 2018 |
Last Verified: | June 2018 |
Diabetes Mellitus, Type 2 Diabetes Mellitus Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Sitagliptin Phosphate Gliclazide Hypoglycemic Agents |
Physiological Effects of Drugs Incretins Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Dipeptidyl-Peptidase IV Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |